PI Perspective 24: Indinavir in Women

PI Perspective 24: Indinavir in Women

Project Inform - April, 1998

Little is known about the effects of hormones on the metabolism, potential effectiveness or side effects of drugs in women. A small study looking at the effects of the menstrual cycle on indinavir (Crixivan©) levels in the blood found dramatic differences in time to peak level and time to optimal therapeutic levels based on the various phases of the menstrual cycle over the course of a month. While the amount of indinavir in the blood appeared to change throughout the hormone cycle, it still remained broadly within the ranges observed in earlier studies that primarily included men. These monthly fluctuations need to be further studied to determine their implications on the durability of the regimen, resistance, dosing and possible long-term toxicity. Fortunately, there are several other studies looking at the use of antiretroviral therapy specifically in women, either in development or enrolling, that may have the opportunity to address these questions.

980401
PI980406

Always watch for outdated information. This article first appeared in 1998. This material is designed to support, not replace, the relationship that exists between you and your doctor.

©1998. This document is copyrighted by Project Inform, 205 13th Street, #2001, San Francisco, CA 94103. Treatment Hotline: 800-822-7422 (toll-free) or 415-558-9051 (in the San Francisco Bay Area and internationally) All Project Inform materials may be reprinted and/or distributed without prior permission. However, reprints may not be edited and must include the following text: "From Project Inform, for more information contact the Project Inform National HIV/AIDS Treatment Hotline, 800-822-7422." For permission to edit any Project Inform material for further publication, contact David Evans at the Project Inform office.

Project Inform, established in 1985 as a national, non profit, community-based HIV/AIDS treatment information and advocacy organization, serves HIV-infected individuals, their care-givers, and their healthcare and service providers through its national, toll-free treatment hotline, the PI Perspective and other information publications, educational Town Meetings, on-line services and research and drug access advocacy programs. All information is available free of charge; donations are strongly encouraged. For more information, contact the Project Inform National HIV/AIDS Treatment Hotline. Email: web@projinf.org; Website: http://www.projinf.org.

The original of this article can be found at http://www.projinf.org/pub/24/antiviral.html

This information is designed to support, not replace, the relationship that exists between you and your doctor.
©1998. AEGiS.